U.S. Markets open in 8 hrs 12 mins

CNS Pharmaceuticals, Inc. (CNSP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.8000-0.0400 (-2.17%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.8400
Open1.8600
Bid0.0000 x 900
Ask0.0000 x 3000
Day's Range1.7700 - 1.8950
52 Week Range1.5900 - 5.6200
Volume227,888
Avg. Volume1,742,830
Market Cap45.542M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.6370
Earnings DateMar 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.33
  • CNS Pharmaceuticals to Participate in Inaugural Emerging Growth Virtual Conference
    PR Newswire

    CNS Pharmaceuticals to Participate in Inaugural Emerging Growth Virtual Conference

    CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals will present at the inaugural Emerging Growth Virtual Conference presented by M Vest LLC and Maxim Group LLC. The conference will take place virtually on March 17th and 18th and will feature roundtable discussions with C-suite executives moderated by Maxim Research Analysts, fireside chats with live Q&A, and presentations from hundreds of issuers both domestically and internationally.

  • CNS Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
    PR Newswire

    CNS Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference

    CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.

  • CNS Pharmaceuticals Berubicin Trial is On Schedule to Commence in March 2021
    PR Newswire

    CNS Pharmaceuticals Berubicin Trial is On Schedule to Commence in March 2021

    CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today indicated that the clinical program for Berubicin is on track to start enrolling patients in March 2021. CNS' lead product candidate, Berubicin, is a novel anthracycline and the first anthracycline to cross the blood-brain barrier. It is in development for the treatment of a number of serious brain and CNS oncology indications.